1. Introduction {#sec1}
===============

Peroxisome proliferator-activated receptor gamma (PPARG) is one of the three PPARs isotypes; the other two are PPAR*α* and PPAR*β*/*δ*. The PPARG is mainly expressed in adipose tissue whilst PPAR*α* is expressed mostly in brown adipose tissue and liver, and PPAR*β*/*δ*, which is found in many tissues, is mostly expressed in gut, kidney, and heart \[[@B1], [@B2]\]. Expression of PPARs occurs when heterodimers are formed with the retinoid X receptor (RXR) and binds to specific PPAR responsive elements of DNA to promote transcription. The PPAR: RXR complex is activated via ligand binding to PPARs resulting in the release of corepressors bound to the receptor and recruitment of coactivators to initiate transcription of target genes \[[@B3]--[@B5]\]. For example, antidiabetic drugs of the thiazolidinedione family are believed to target the transcription factor PPARG to improve insulin sensitivity in type 2 diabetes (T2D) and induce glucose transporter 4 mRNA expression in fat and muscle \[[@B6]--[@B8]\].

Naturally occurring PPARG polymorphisms have been described in several studies. The two common variants of the PPARG gene, Pro12Ala and His447His, have been associated with metabolic states of obesity, insulin resistance, type 2 diabetes, and metabolic syndrome \[[@B9]\]. The His447His polymorphism (also referred to as C161T, C1431T, or CAC478CAT, His449His) is a silent mutation at exon 6 and is considered a better predictor of fasting insulin levels and insulin resistance than Pro12Ala \[[@B10]\]. In our previous analysis, the presence of*PPARG* Pro12 conferred a 64% higher risk of prevalent type 2 diabetes, but we failed to demonstrate an association with markers of insulin resistance \[[@B11]\]. In the present study, we therefore investigated the association between cardiometabolic traits, His447His, and other PPARG polymorphisms.

2. Materials and Methods {#sec2}
========================

2.1. Baseline Evaluations {#sec2.1}
-------------------------

This investigation is based on the Bellville South cohort from Cape Town, South Africa, which has received study approval from the Research Ethics Committees of the University of Stellenbosch (HREC reference number N09/05/146) and Cape Peninsula University of Technology Faculty of Health and Wellness Sciences Ethics Committee (reference numbers CPUT/HW-REC 2008/002 and CPUT/HW-REC 2010). The study was conducted according to the code of ethics of the World Medical Association (Declaration of Helsinki). A detailed description of the research setting has been previously described \[[@B12], [@B13]\]. Briefly, Bellville South is predominantly a mixed ancestry township located in the northern suburb of Cape Town in the Tygerberg subdistrict. The mixed ancestry, commonly referred to as coloured, is a South African population group with 32--43% Khoisan, 20--36% Bantu-speaking African, 21--28% European, and 9--11% Asian ancestry \[[@B14]\]. All participants received a standardized interview and physical examination during which blood pressure was measured according to the World Health Organisation (WHO) guidelines \[[@B15]\] using a semiautomated digital blood pressure monitor (Rossmax PA, USA) on the right arm in a sitting position. Anthropometric measurements were performed three times and their average was used for analysis: weight (kg), height (cm), waist (cm), and hip (cm) circumferences. Participants with no history of doctor-diagnosed diabetes mellitus underwent a 75 g oral glucose tolerance test (OGTT) as recommended by the WHO \[[@B16]\]. Further, the following biochemical parameters were determined on the Cobas 6000 Clinical Chemistry instrument (Roche Diagnostics, Germany): fasting plasma glucose, insulin, creatinine, total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), triglycerides (TG), C-reactive protein (CRP), *γ*-glutamyltransferase (GGT), and glycated haemoglobin (HbA1c) certified by the National Glycohemoglobin Standardisation Programme (NGSP). Low density lipoprotein cholesterol (LDL-c) was calculated using Friedewald\'s formula \[[@B17]\].

2.2. SNP Genotyping {#sec2.2}
-------------------

Genomic DNA was extracted from whole blood samples collected in an EDTA tube. Single nucleotide polymorphisms (SNPs) in the PPARG, Pro115Gln (rs1800571, G\>T), Val290Met (rs72551362, G\>A), Pheu388Leu (rs72551363, T\>A), Arg397Cys (rs72551364, C\>T), and His447His (rs3856806, C\>T), were genotyped using high throughput real-time polymerase chain reaction (RT-PCR) in two independent laboratories on the ABI Prism 7900HT platform (Applied Biosystems, USA) and a Bio-Rad Optica (BioRad, USA) using TaqMan genotyping assay (Applied Biosystems, USA). Conventional polymerase chain reaction followed by direct DNA sequencing was performed for analytical validation of high throughput genotyping.

2.3. Definitions and Calculations {#sec2.3}
---------------------------------

Body mass index (BMI) was calculated as weight per square meter (kg/m^2^) and waist-hip-ratio (WHR) as waist/hip circumferences (cm). Type 2 diabetes status was based on a history of doctor-diagnosis, a fasting plasma glucose ≥7.0 mmol/L, and/or a 2-hour post-OGTT plasma glucose ≥11.1 mmol/L. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated according to the formula HOMA-IR = fasting insulin concentration (mIU/L) × fasting plasma glucose (mmol/L)/22.5, while functional *β*-cells (HOMA-B%) were estimated using the formula 20 × fasting insulin (*μ*IU/mL)/fasting glucose (mmol/mL) − 3.5. The fasting insulin resistance index (FIRI) was calculated with the formula (fasting insulin (*μ*U/mL) × fasting glucose (mM))/25 and the quantitative insulin-sensitivity check index (QUICKI) was calculated as 1/log fasting insulin (*μ*U/mL) × log (fasting glucose (mg/dL)). Glomerular filtration rate (GFR) was estimated by the 4-variable modification of diet in renal disease (MDRD) equation \[[@B18], [@B19]\] applicable to standardised serum creatinine values.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Of the 946 participants who took part in the survey, 941 consented for genetic studies. Among the latter, 121 were excluded for missing data on the genetic variables. Therefore, 820 had valid data for the current analyses. General characteristics of the study group are summarized as count and percentage for dichotomous traits, mean and standard deviation (SD), or median and 25th--75th percentiles for quantitative traits. Traits were log-transformed to approximate normality, where necessary, prior to analysis. SNPs were tested for departure from Hardy-Weinberg equilibrium (HWE) expectation via a chi-square goodness of fit test. Linear regression models were used for the analysis of quantitative traits and logistic regression models for dichotomous traits, always assuming additive models for the SNPs. Using linear and logistic models enabled us to adjust all analyses for known confounders as specified everywhere in the results. We investigated the additive allelic association of each SNP with each trait, overall and according to type 2 diabetes status, and tested for heterogeneity by adding the interaction term of type 2 diabetes and each SNP to a model that contained the main effects of type 2 diabetes and the relevant SNP. Results corresponding to *P* values below 5% are described as significant. We did not adjust for multiple testing. All analyses used the statistical package R (version 3.0.0 (2013-04-03), The R Foundation for Statistical Computing, Vienna, Austria).

3. Results {#sec3}
==========

Clinical characteristics of participants overall and according to diabetes status are summarized in [Table 1](#tab1){ref-type="table"} indicating that 222 (27%) participants had type 2 diabetes. As expected, the distribution of the level of insulin resistance/sensitivity indicators was significantly different between the two groups all *P* \< 0.0001, except for glucose/insulin ratio (*P* = 0.0304). Furthermore, compared with nondiabetic participants, those with diabetes were significantly older (58.9 versus 51.0 years, *P* \< 0.0001) and had higher levels of adipometric variables (all *P* ≤ 0.014), systolic blood pressure (*P* \< 0.0001), triglycerides (*P* \< 0.0001), GGT, and CRP (both *P* \< 0.0001), whilst eGFR (*P* = 0.029) and HDL cholesterol (*P* = 0.0002) were significantly lower.

No mutations were found for the following SNPs of PPARG: Pro115Gln, Val290Met, Pheu388Leu, and Arg397Cys. The PPARG, His447His, variant was in HWE (*P* \> 0.05) and its genotype and allele distribution overall and by diabetes status are summarized in [Table 2](#tab2){ref-type="table"}. The frequency of the PPARG (rs3856806), C/T genotype, was 23.8% in the overall population group and the genotype distributions did not differ significantly between the nondiabetic and diabetic groups. Overall, the T allele frequency was 14%; however, although not significant (*P* = 0.128), the T allele did occur more in the nondiabetic (14.8%) than in the diabetic (11.7%) participants.

In generalized linear regression analyses adjusted for age, sex and diabetes ([Table 3](#tab3){ref-type="table"}), PPARG His447His allele T was associated with none of the markers of insulin resistance overall and by diabetes status. There was a borderline statistical interaction in the effect by diabetes status for the association with fasting glucose (interaction *P* = 0.092), HOMA-IR and FIRI indices (both *P* = 0.076). Furthermore, the effects always appeared to be sizable and negative (although nonsignificant) among the diabetic and almost null in nondiabetic participants.

In the logistic regression models ([Table 4](#tab4){ref-type="table"}) PPARG allele T was associated with odds ratio of 0.76 (95% confidence interval 0.55--1.05) for prevalent diabetes. The effect estimates broadly remained within the same range after adjustment for age and sex, with or without further adjustment for various indices of insulin resistance/sensitivity. However, in model containing sex, age, and 2-hour insulin, PPARG allele T was significantly associated with a lower prevalent diabetes risk with an odds ratio of 0.56 (95% CI: 0.31--0.95).

4. Discussion {#sec4}
=============

The present study reports five PPARG SNPs, rs1800571, rs72551362, rs72551363, rs72551364, and rs3856806. Only His447His (rs3856806) was found to be polymorphic and demonstrated an association with diabetes risk. The T allele frequencies were about 14% and, in an additive genetic model, we observed that the presence of the T allele significantly reduced the risk of diabetes by 44%. Furthermore, the T allele was associated with reduced fasting blood glucose levels and HOMA-IR and FIRI indices. However these associations were borderline and did not reach statistical significance.

The nuclear transcription receptor, PPARG, acts as a regulator of adipocyte differentiation, pancreatic beta cell function, and lipid and glucose metabolism \[[@B20]--[@B22]\]. Despite its biological plausibility, previously reported association studies with obesity \[[@B23]--[@B25]\], insulin resistance \[[@B10], [@B25]\], type 2 diabetes \[[@B11], [@B26]\], and metabolic syndrome \[[@B27]\] are conflicting. For instance, some studies have reported that carriers of the T allele of His447His (rs3856806) have increased obesity risk \[[@B23]\], poor lipid profile \[[@B28]--[@B30]\], and risk of metabolic syndrome \[[@B27]\] and coronary heart diseases (CHD) \[[@B9]\]. On the other hand, others have failed to demonstrate an association between PPARG SNPs including C161T with CHD susceptibility \[[@B31]\], whilst some have shown increased insulin sensitivity \[[@B10], [@B26]\], decreased CHD, body mass index, and diabetes risk \[[@B25], [@B26], [@B29], [@B32]\] in subjects harbouring the T allele. In our study, presence of the T allele was associated with reducing the risk of prevalent diabetes and levels of insulin resistance indices. Aspects that may contribute to the inconsistencies in these studies include variations in ethnic distribution of PPARG polymorphisms, the statistical power of the studies, environmental-gene and gene-gene factors, and different levels of adjustment for potential confounding factors across studies. For example, in our study, the T allele frequency of the His447His variant (14%) was similar to that reported in the Australian Caucasians, 16.3% \[[@B2]\], and the Tunisians, 18.3% \[[@B27]\], whilst in the Chinese a frequency of 29.2% has been reported \[[@B33]\]. Furthermore, two recent studies have shown that gene-gene interaction analysis is superior to single PPARG polymorphisms for the quantification of effects with cardiometabolic traits \[[@B33], [@B34]\]. For example, Luo et al. \[[@B33]\] investigated the association of 10 PPARG SNPs with obesity and found that only two SNPs, rs2016520 and rs10865170, were associated with lower obesity risk. However, in generalized multifactor dimensionality reduction analysis to assess the effect of interaction among the 10 SNPs, an additional SNP, rs9794, was identified and showed a potential gene-gene interaction with rs2016520 and rs10865170 \[[@B33]\].

We also genotyped some of the PPARG SNPs, rs1800571, rs72551362, rs72551363, and rs72551364, but no genetic variations were observed. The rs1800571, Pro115Gln, gain-of-function mutation has only been found in five German morbid obese subjects since its initial identification by Ristow et al. \[[@B35]\], where three of the four obese subjects with the genetic variant also had type 2 diabetes. In another German population study, another carrier of the mutant with severe insulin resistance was identified \[[@B36]\]. However, other studies involving German, Danish, and American populations failed to find this mutation \[[@B37]--[@B40]\]. Similarly, there has not been more than one individual in which either rs72551362, rs72551363, or rs72551364 has been found \[[@B41]--[@B43]\]. The rare nature of these mutations suggests that standard population-based type studies are likely not the suitable design to investigate them, considering the requirements for very large sample size. Rather, targeting specific segments of the population such as people with morbid obesity for screening may increase the likelihood of uncovering some with the mutation. It is also possible that mutations other than those reported so far could be present in other populations, indicating the need for genome-wide scanning studies in different setting to capture additional mutations.

Our study has some limitations and these include the investigation of only five SNPs and small sample size. However, the participants in this study were well characterised and we used both fasting and oral glucose tolerance test derived indices for the assessment of type 2 diabetes and insulin resistance. In conclusion, our study confirmed the almost zero occurrences of known rare PPARG SNPs and has shown that one of the common SNPs, His447His, may be protective against type 2 diabetes. Future larger studies with more SNPs involving populations from Africa need further exploration.
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###### 

General characteristics of the overall population and by diabetic status.

  Variable                                             No diabetes            Diabetes               *P*-value   Overall
  ---------------------------------------------------- ---------------------- ---------------------- ----------- ----------------------
  Number                                               **598**                **222**                            **820**
  Gender, male *n* (%)                                 130 (21.7)             48 (21.6)              0.9474      178 (21.7)
  Mean age, year (SD)                                  51.0 (15.1)            58.9 (13.4)            \<0.0001    53.2 (15.1)
  Mean systolic blood pressure, mmHg (SD)              122 (19)               130 (23)               \<0.0001    124 (21)
  Mean diastolic blood pressure, mmHg (SD)             75 (12)                77 (14)                0.0506      76 (13)
  Hypertension, *n* (%)                                314 (52.5)             133 (59.9)             0.05859     447 (54.5)
  Mean body mass index, kg/m^2^ (SD)                   29.2 (7.0)             31.8 (7.1)             \<0.0001    29.9 (7.1)
  Mean waist circumference, cm (SD)                    95 (15)                102 (14)               \<0.0001    97 (15)
  Mean hip circumference, cm (SD)                      109 (14)               112 (15)               0.014       109 (14)
  Mean waist/hip ratio, (SD)                           0.87 (0.10)            0.91 (0.10)            \<0.0001    0.88 (0.09)
  Mean HbA1c, % (SD)                                   5.7 (0.4)              7.8 (2.1)              \<0.0001    6.3 (1.4)
  Mean fasting blood glucose, mmol/L (SD)              5.1 (0.7)              9.8 (4.5)              \<0.0001    6.4 (3.2)
  Mean 2 h glucose, mmol/L (SD)                        6.4 (1.6)              13.4 (5.3)             \<0.0001    7.5 (3.6)
  Mean eGFR, mL/min (SD)                               76.2 (21.2)            72.0 (25.2)            0.029       75.0 (22.4)
  Mean triglycerides, mmol/L (SD)                      1.4 (0.9)              1.7 (0.9)              \<0.0001    1.5 (0.9)
  Mean HDL cholesterol, mmol/L (SD)                    1.3 (0.4)              1.2 (0.3)              0.0002      1.3 (0.4)
  Mean LDL cholesterol, mmol/L (SD)                    3.6 (1.0)              3.7 (1.1)              0.179       3.6 (1.0)
  Mean total cholesterol, mmol/L (SD)                  5.5 (1.2)              5.7 (1.3)              0.068       5.6 (1.2)
  Median GGT (25th--75th percentiles)                  26 \[17--39\]          32 \[23--49\]          \<0.0001    27 \[19--42\]
  Median CRP (25th--75th percentiles)                  3.3 \[0.9--8.3\]       5.4 \[2.2--10.9\]      \<0.0001    4.0 \[1.2--9.4\]
  Median insulin mmol/L (25th--75th percentiles)       7.2 \[3.4--12.9\]      10.2 \[4.4--17.6\]     0.0001      7.7 \[3.5--14.1\]
  Median 2 h insulin mmol/L (25th--75th percentiles)   36.0 \[19.3--65.7\]    53.3 \[22.1--117.0\]   0.0015      37.3 \[19.5--72.7\]
  Median glucose/insulin (25th--75th percentiles)      0.71 \[0.40--1.45\]    0.82 \[0.48--2.05\]    0.0304      0.72 \[0.41--1.58\]
  Median HOMA-IR (25th--75th percentiles)              1.63 \[0.69--3.00\]    3.67 \[1.71--7.29\]    \<0.0001    1.94 \[0.86--3.82\]
  Median HOMA-B% (25th--75th percentiles)              92.8 \[43.5--165.1\]   42.1 \[13.6--83.4\]    \<0.0001    74.2 \[32.2--149.2\]
  Median QUICKI (25th--75th percentiles)               0.15 \[0.14--0.18\]    0.14 \[0.12--0.15\]    \<0.0001    0.15 \[0.14--0.17\]
  Median FIRI (25th--75th percentiles)                 1.46 \[0.62--2.70\]    3.31 \[1.54--6.56\]    \<0.0001    1.74 \[0.77--3.44\]
  Median 1/HOMA-IR (25th--75th percentiles)            0.61 \[0.33--1.44\]    0.27 \[0.14--0.58\]    \<0.0001    0.52 \[0.26--1.16\]

CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; FIRI: fasting *insulin*-resistance index; GGT: *γ*-glutamyltransferase; HbA1c: glycated haemoglobin; HDL: high density lipoproteins; HOMA-B%: functional *β*-cells; HOMA-IR: homeostatic model assessment of insulin resistance; LDL: low density lipoproteins; QUICKI: the quantitative *insulin*-sensitivity check index; SD: standard deviation.

###### 

Genotype distributions, minor allele frequencies, and unadjusted *P*-values for comparing genotype distribution according to diabetes status and additive allelic effects between diabetes groups.

                      No diabetes   Diabetes     *P*-value   Overall
  ------------------- ------------- ------------ ----------- ------------
  *N*                 **598**       **222**                  **820**
  PPARG (rs3856806)                                           
   C/C, *n* (%)       436 (72.9)    172 (77.5)   0.215       608 (74.1)
   C/T, *n* (%)       147 (24.5)    48 (21.6)                195 (23.8)
   T/T, *n* (%)       15 (2.5)      2 (0.9)                  17 (2.1)
   T, *n* (%)         177 (14.8)    52 (11.7)    0.128       229 (14.0)
  HWE (*P*-value)     0.517         0.747                    0.771

HWE: Hardy-Weinberg equilibrium (HWE *P*-values are from exact tests); PPARG: peroxisome proliferator-activated receptor gamma.

###### 

Generalized linear regression models showing the effects of genes on markers of insulin resistance/sensitivity.

  Allele               Phenotype                   Overall                    No diabetes                Diabetes                   *P* interaction                                                  
  -------------------- --------------------------- -------------------------- -------------------------- -------------------------- ----------------------------- -------------------------- ------- -------
  PPARG (rs3856806)T   Fasting glucose             −0.140 (−0.480 to 0.199)   0.417                      0.0002 (−0.112 to 0.112)   0.996                         −0.606 (−1.934 to 0.722)   0.372   0.092
  2 h glucose          −0.114 (−0.494 to 0.266)    0.557                      −0.098 (−0.341 to 0.144)   0.426                      −0.147 (−2.826 to 2.533)      0.915                      0.847   
  HbA1c                −0.018 (−0179 to 0.143)     0.826                      0.034 (−0.031 to 0.099)    0.303                      −0.211 (−0.829 to 0.407)      0.504                      0.164   
  Fasting insulin      −0.915 (−3.362 to 1.533)    0.464                      0.022 (−1.420 to 1.463)    0.976                      −4.516 (−13.448 to 4.416)     0.323                      0.125   
  2 h insulin          −1.716 (−11.818 to 8.386)   0.739                      0.408 (−9.473 to 10.289)   0.936                      −20.212 (−62.232 to 21.807)   0.348                      0.190   
  Glucose/insulin      −0.488 (−1.905 to 0.929)    0.500                      −0.083 (−1.258 to 1.091)   0.890                      −1.743 (−6.271 to 2.785)      0.451                      0.334   
  HOMA-IR              −0.437 (−1.481 to 0.608)    0.413                      0.021 (−0.327 to 0.368)    0.907                      −2.228 (−6.336 to 1.880)      0.289                      0.076   
  QUICKI               0.001 (−0.006 to 0.009)     0.738                      0.0008 (−0.008 to 0.010)   0.851                      0.004 (−0.009 to 0.016)       0.564                      0.752   
  FIRI                 −0.393 (−1.333 to 0.547)    0.413                      0.019 (−0.294 to 0.332)    0.907                      −2.005 (−5.703 to 1.692)      0.289                      0.076   

Models are adjusted for age, sex, and diabetes. FIRI: fasting insulin resistance index; HOMA-IR: homeostatic model assessment of insulin resistance; PPARG: peroxisome proliferator-activated receptor gamma; QUICKI: the quantitative insulin-sensitivity check index.

###### 

Odds ratio and 95% confidence intervals from logistic regression for the prediction of diabetes.

  Allele                      Covariates            OR (95% CI)           *P*
  --------------------------- --------------------- --------------------- -------
  PPARG (rs3856806)T          None                  0.76 (0.55 to 1.06)   0.112
  sex, age                    0.74 (0.53 to 1.03)   0.082                 
  sex, age, insulin           0.75 (0.53 to 1.05)   0.098                 
  sex, age, 2 h insulin       0.56 (0.31 to 0.95)   0.042                 
  sex, age, HOMA-IR           0.77 (0.53 to 1.10)   0.157                 
  sex, age, QUICKI            0.75 (0.53 to 1.04)   0.094                 
  sex, age, FIRI              0.77 (0.53 to 1.10)   0.157                 
  sex, age, glucose/insulin   0.75 (0.53 to 1.04)   0.092                 

FIRI: fasting insulin resistance index; HOMA-IR: homeostatic model assessment of insulin resistance; PPARG: peroxisome proliferator-activated receptor; QUICKI: the quantitative insulin-sensitivity check index.
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